Meeting
2017 Genitourinary Cancers Symposium
Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.
Authors
Andrea Necchi
Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan, Italy
Andrea Necchi , Salvatore Lo Vullo , Patrizia Giannatempo , Daniele Raggi , Giuseppina Calareso , Elena Togliardi , Flavio Crippa , Marzia Pennati , Nadia Zaffaroni , Federica Perrone , Nicola Nicolai , Luigi Mariani , Roberto Salvioni , Maurizio Colecchia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Clinical Trial Registration Number
NCT01743482
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 414)
DOI
10.1200/JCO.2017.35.6_suppl.414
Abstract #
414
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.
First Author: Patrizia Giannatempo
Poster
2016 Genitourinary Cancers Symposium
Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01).
First Author: Andrea Necchi
Poster
2019 ASCO Annual Meeting
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
First Author: Darren R. Feldman
Poster
2018 ASCO Annual Meeting
Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.
First Author: Daniele Raggi